Gilead Sciences

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers.

News

Gilead tries again with twice-yearly HIV drug lenacapavir

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in Februa

News

ASCO22: Gilead makes case for Trodelvy in advanced breast ca...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hope

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

News

Gilead dives deeper into NK cell therapies with Dragonfly de...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cance

News

Gilead wins court order against fraudsters targeting HIV pro...

Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent r

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

Gilead tries again with twice-yearly HIV drug lenacapavir

ASCO22: Gilead makes case for Trodelvy in advanced breast ca...

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Gilead dives deeper into NK cell therapies with Dragonfly de...

Gilead wins court order against fraudsters targeting HIV pro...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks